A highly anticipated COVID-19 vaccine which is being jointly developed by AstraZeneca and Oxford University has produced encouraging results in a phase 1/2 trial. The phase 1/2 results, published in The Lancet demonstrated that the vaccine, AZD1222, produced a robust immune response against the SARS-CoV-2 virus in all participants in the study. The vaccine also proved safe to use,
AstraZeneca will start clinical trials of two antibodies targeting SARS-CoV-2, the virus that causes COVID-19, within the next two months. The two candidates have emerged from a partnership with Vanderbilt University in the US – focusing on up to six coronavirus-targeting neutralising antibodies – which was signed in April. The antibodies have the potential to
Recent trial data has shown that AstraZeneca’s Dapagliflozin cut the relative risk of major adverse cardiovascular events (MACE) by 16% compared to placebo in patients with type II diabetes who had a prior heart attack. In a second pre-specified sub-analysis of data from the DECLARE-TIMI 58 study, the SGLT2 inhibitor reduced the relative risk of
AstraZeneca has reported positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) of BMS-512148 compared to placebo for the treatment of patients with type 2 diabetes (T2D). The trial had met its primary safety objective of non-inferiority for major adverse cardiovascular events (MACE). The trial also achieved one of its two
AZ announce data that it says will establish its lung cancer drug Tagrisso as standard second line treatment in patients with certain mutations. The data showed Tagrisso slowed tumour progression compared with standard chemotherapy and was also more effective in patients with brain metastases. Tagrisso is approved in second line non-small cell lung cancer with
A consortium of international pharmaceutical firms and UK universities have launched a new £40m fund for early drug research.
A three year partnership between AstraZeneca (AZ) and French National Institute of Health and Medical Research (Inserm) is aiming to advance the understanding of biological mechanisms that come with the conditions. Based on the findings, they hope to develop new therapeutic approaches to type 2 diabetes and chronic kidney disease.
cialis Xigduo, Launched in the UK” src=”http://i39.tinypic.com/hwxyt2.jpg” width=”230″ height=”80″ />Type II diabetes patients living in England and Wales have gained access to a new treatment option to improve blood glucose levels after AstraZeneca launched their diabetes drug, Xigduo, earlier this week. Xigduo combines BMS-512148 and metformin in a twice-daily tablet for use in patients inadequately
Patients with diabetes in Scotland have gained routine access to AstraZeneca/ Bristol-Myers Squibb’s Forxiga on the UK National Health Service (NHS) after it was considered cost-effective by the Scottish Medicines Consortium (SMC). The SMC have dispensed guidance to healthcare professionals approving the use of the first-in-class drug Forxiga (BMS-512148) in adults with type 2 diabetes
AstraZeneca have reinforced their interest in China by entering into a joint venture between their biotechnology arm MedImmune, and Chinese firm WuXi AppTec, which seeks to quicken the development of a new medicine for inflammatory conditions in the country. Under the joint venture, in which the two organisations will have equal ownership, MedImmune’s experimental, fully-human